

Application No. 10/550,038
Amendment Dated 03/10/2006
Reply to Office Action of 03/09/2006
Page 9 of 10

Remarks/Arguments:

Claims 1, 2, 4, 6, 8, and 11 to 13 are pending and under examination in the instant application. Claim 6 has been amended so that its scope is consistent with the subject matter previously elected by Applicants. No new matter has been added by this amendment.

Obviousness-Type Double Patenting

The Examiner rejected the present claims over those of copending U.S. Application No. 10/550,039. As the Examiner noted, because the '039 Application has not been patented, the rejection is a provisional rejection.


However, in the interest of furthering prosecution of the instant application, Applicants would be willing to file a terminal disclaimer if necessary.

Applicants believe the application is now in condition for allowance, which action is respectfully requested.

Application No. 10/550,038
Amendment Dated 08/10/2006
Reply to Office Action of 06/09/2006
Page 10 of 10

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100869-1P US.

Respectfully submitted,


Name: John X. Haberman
Dated: August 10, 2006
Reg. No.: 55,236
Phone No.: 781-839-4736
Global Intellectual Property, Patents
AstraZeneca R&D Boston
35 Gatehouse Drive
Waltham, MA 02451